Δ-10-Tetrahydrocannabinol
Viewing r1 — May 7, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Δ10-THC (delta-10-tetrahydrocannabinol) is a semi-synthetic cannabinoid of the terpenophenolic class. It is a positional isomer of Δ9-THC, sharing the same molecular skeleton but with a double bond shifted one position in the ring. Unusually, it blocks rather than activates the brain's primary cannabinoid receptor.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
No dose data on record for this route. The timings below are not a dose guide.
First produced in 1984 as a byproduct of cannabinoid isomerization research,[2] Δ10-THC attracted no scientific interest for over three decades. It was accidentally rediscovered around 2020, when a California extraction company found unusual crystals forming in wildfire-contaminated cannabis distillate.[3] It is now sold widely across the United States in vapes, edibles, and blended hemp products.[4]
Subjective effects include mild euphoria, mental stimulation, relaxation, and less anxiety than Δ9-THC. The experience is clear-headed and energizing — closer to a sativa-type cannabis feel than the heavier sedation typical of other THC isomers. Rapid heart rate, agitation, and unexpected sedation are the main unsought effects.[5]
No dependence data exist and no lethal dose has been established. The chief danger is product quality: the chemical conversion process used to make it can leave unknown byproducts and contaminants.[6] Understanding is extremely thin — no controlled human studies have been done, and available data cannot isolate Δ10-THC's effects from those of the other cannabinoids it is typically combined with.
History[edit]
History
Discovery
Δ10-THC was first produced in 1984 at the Hebrew University of Jerusalem. Researchers led by Mechoulam were exploring how the double bond in THC could be moved to different positions in the ring.[2] The Δ10 isomer appeared as a side product — no one studied its effects, and it sat unexamined for over thirty years.
Rediscovery and commercialization
Around 2019–2020, a California extraction company purchased cannabis biomass contaminated with aerial fire retardant from wildfire season. Unusual crystals formed during distillation; organic chemist Josh Jones identified them by NMR spectroscopy as Δ10-THC and developed a scalable production method using food-grade acid catalysts.[3] The 2018 US Farm Bill — legalizing hemp-derived products below 0.3% Δ9-THC — opened a commercial path.
Present status
By 2023, Δ10-THC was one of the six most prevalent intoxicating compounds in the US hemp market.[4] This rapid adoption occurred with virtually no pharmacological or safety research — a pattern shared with Δ8-THC and other hemp-derived cannabinoids.[7]
The name "Δ10-THC" marks where the double bond sits in the ring — C10–C10a instead of C9–C10 (Δ9-THC) or C8–C9 (Δ8-THC). The compound has no established street names and circulates commercially under its chemical abbreviation.
Chemistry[edit]
Chemistry
Structural identity
Δ10-THC belongs to the terpenophenolic cannabinoid family — the same structural class as Δ9-THC and Δ8-THC. It differs from Δ9-THC only in where a double bond sits in the cyclohexene ring: one position over, at C10–C10a instead of C9–C10. Its molecular formula is C₂₁H₃₀O₂ — identical to Δ9-THC and Δ8-THC — meaning standard cannabinoid tests cannot distinguish them without specialized chromatography or NMR analysis.
Pharmacology[edit]
Pharmacology
Mechanism of action
Δ10-THC interacts with the endocannabinoid system through CB1 and CB2 receptors, but behaves unlike any other THC isomer. Lab studies show it binds CB1 but blocks rather than activates it.[1] Δ9-THC, Δ8-THC, and every other characterized THC isomer activate CB1 — making Δ10-THC's blocking behavior unprecedented in this family.
In mice, Δ10-THC produced some Δ9-THC-like behavioral effects, but only at very high doses that also heavily suppressed overall activity.[8] Possible explanations include the body converting it to an active metabolite, or effects running through CB2 rather than CB1. Whether it produces its effects through CB1, CB2, or another pathway in humans is not established.
Pharmacokinetics
No pharmacokinetic data exist for Δ10-THC in humans or animals. All estimates are projected from Δ9-THC and should not be treated as measured values.[9] inferred Inhaled bioavailability is estimated at 10–35%; oral bioavailability at 4–12%. Plasma half-life is estimated at 1–3 days in occasional users and 5–13 days in regular users.
Neuroscience[edit]
Neuroscience
Where it acts
Cannabis works primarily through CB1 receptors distributed across brain circuits involved in memory, mood, appetite, and stress. Activating these receptors suppresses neurotransmitter release, producing the classic cannabis profile: altered time perception, memory suppression, appetite changes, and context-dependent mood shifts.
Δ10-THC blocks CB1 rather than activating it.[1] A blocker would be predicted to do the opposite of cannabis — increasing neurotransmitter release, potentially causing anxiety rather than relaxation, and suppressing appetite. That anecdotal reports describe mild euphoria suggests either the body converts it into something active, or a different receptor is responsible.
Why it matters
Δ10-THC is rarely used alone — commercial products frequently blend it with Δ8-THC, Δ9-THC, and other cannabinoids.[4] It may modulate those co-consumed cannabinoids rather than acting independently — softening anxiety while other compounds provide euphoria. This is speculative; no human data confirm it.
Subjective Effects[edit]
Subjective Effects
Δ10-THC produces a mild, clear-headed experience that leans toward stimulation rather than sedation. Users describe a gentle euphoria — present but not overwhelming, without the cognitive fog or body heaviness that Δ9-THC commonly produces. Its CB1-blocking profile may explain this lighter character.
Among THC isomers, it is reported as the mildest — lighter than both Δ9-THC and Δ8-THC.[1] Users compare it to sativa-type cannabis: an uplifting quality without heavy sedation. Most commercial products are blends, so the experience in practice is shaped by whatever other cannabinoids are present.[4]
Timeline
Slow gastrointestinal absorption delays first effects to 30–90 minutes post-ingestion. Initial awareness is subtle — a mild shift in mood or slight perceptual change that may be difficult to distinguish from placebo.
Gradual intensification over 1–2 hours as absorption continues. Effects build slowly and unevenly. Mild cognitive euphoria, emerging stimulation, and increasing body awareness develop.
Maximum intensity 2–4 hours post-ingestion. The full effect profile emerges — cognitive euphoria, mild time alteration, stimulation, and physical effects including dry mouth and possible tachycardia. Reported as milder and more clear-headed than oral Δ9-THC.
Gradual decline over 2–4 hours. Cognitive effects diminish before physical effects. Residual dry mouth, mild fatigue, and subtle appetite changes may linger as the experience resolves.
Residual effects may persist for several hours — subtle mood changes, mild physical fatigue, or lingering appetite shifts. Cognitive function returns to near-baseline but subclinical impairment may remain longer than perceived.
⚠ Do not drive or operate heavy machinery for at least 8 hours after oral use.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- Δ9-THC · Δ8-THC · other CB1 receptor agonists
Safety
Toxicity
No lethal dose has been established for Δ10-THC. No deaths attributable to Δ10-THC alone appear in published literature.
The only clinical toxicity data come from US poison center surveillance of combined exposures to Δ8-THC, Δ10-THC, and THC-O acetate.[5] Δ8-THC accounted for 98.1% of cases; Δ10-THC's contribution was not quantified separately. The pooled presentation included CNS depression (25% of cases), rapid heart rate (23%), agitation (15.6%), and serious medical outcomes in 38.4%. Children under six represented 30.1% of exposures — primarily accidental ingestion of edible products. These figures cannot be directly attributed to Δ10-THC. safety citation needed
Δ10-THC is increasingly present in vape products.[10][11] No pulmonary toxicology data exist for Δ10-THC vapor specifically.
All commercial Δ10-THC carries contamination risk from its manufacturing process: unknown isomers and byproducts,[12] residual solvents and heavy metals,[6] and significant gaps between labeled and actual cannabinoid content.[6][4] safety citation needed
Psychological Risks
No controlled studies have evaluated Δ10-THC's psychological risk profile. Anecdotal reports describe less anxiety and paranoia than Δ9-THC, but this is unconfirmed.
A theoretical risk comes from pharmacological class: rimonabant, a potent CB1 blocker, was withdrawn from European markets after links to depression, anxiety, and suicidal thoughts. Whether Δ10-THC's much weaker CB1 blocking carries any similar risk is unknown and warrants monitoring. safety citation needed No data exist on psychosis, HPPD, or psychiatric destabilization risk specific to Δ10-THC.
Tolerance & Dependence
No tolerance or dependence data exist for Δ10-THC. The closest structural analog with published data is Δ8-THC, which produces tolerance via CB1 receptor downregulation, cross-tolerance to synthetic cannabinoids, and physical dependence in mice.[13]
If Δ10-THC's CB1 blocking profile holds in vivo, the standard mechanism of cannabinoid tolerance — receptor downregulation from sustained activation — would not apply. Cannabis broadly carries a 2–6 day withdrawal involving irritability, sleep disruption, appetite changes, and craving.[14] Whether Δ10-THC shares this is an open question.
Drug Interactions
No published interaction data exist for Δ10-THC. All interactions below are inferred from cannabinoid class pharmacology. inferred
Combined use with alcohol, benzodiazepines, opioids, or other sedatives is expected to increase sedation and impair coordination. Rapid heart rate — documented in 23% of pooled adverse events[5] — may increase cardiovascular strain in combination with stimulants.
Δ10-THC is presumed to be processed by the same liver enzymes as Δ9-THC — CYP3A4 and CYP2C9.[9] These enzymes also handle blood thinners like warfarin, certain antidepressants, immunosuppressants, and antivirals. Competition at CYP2C9 could raise bleeding risk in people taking warfarin. safety citation needed
If Δ10-THC acts as a CB1 blocker in vivo, combining it with antipsychotics may produce unpredictable effects in the endocannabinoid-dopamine system. No data exist.
Contraindications
No substance-specific contraindication data exist for Δ10-THC. The following derive from cannabinoid class pharmacology and adverse event data.
Pregnancy and breastfeeding (absolute): No reproductive toxicity data exist. Cannabinoids as a class cross the placental barrier and are found in breast milk. Avoidance is the standard recommendation. safety citation needed
Pediatric exposure (absolute): Children under six made up 30.1% of poison center cases in the combined dataset, with serious medical outcomes in 38.4%.[5] Products must be stored out of reach of children.
Heart conditions (relative): Rapid heart rate occurred in 23% of pooled adverse events.[5] Those with heart rhythm problems, coronary artery disease, or heart failure face elevated risk.
Blood thinner therapy (relative): Presumed CYP2C9 competition with warfarin and related blood thinners. Monitoring is advisable if co-use occurs. safety citation needed
Psychiatric vulnerability (relative): The rimonabant parallel warrants caution in those with depression, anxiety disorders, or history of suicidal thoughts. No data confirm or refute this risk. safety citation needed
Driving and machinery (relative): No impairment studies exist. General cannabinoid impairment risk applies. Δ10-THC cross-reacts with standard urine drug screens.[15]
Harm Reduction[edit]
Harm Reduction
Forms & Identification
Δ10-THC products exist in an unregulated space where label accuracy is unreliable. Even third-party tested products may not contain what they claim — documented discrepancies between declared and actual cannabinoid content are common.[6][4]
Because Δ10-THC is made by the same conversion process as Δ8-THC, products may contain unknown byproducts and residual solvents that standard cannabinoid panels do not screen for.[12] Full-panel third-party testing — covering residual solvents, heavy metals, and pesticides — is the minimum reasonable quality check.
Set & Setting
Δ10-THC is milder than Δ9-THC, but product variability and blended formulations make actual intensity unpredictable. Start with a low amount and wait for full onset before any additional use. Edibles in particular have delayed and variable onset.
A calm, familiar environment with trusted company is advisable for first use. Blended products — combining Δ10-THC with other cannabinoids — may behave differently from either compound alone.
Guidelines
- Obtain products with full-panel third-party testing including residual solvents and heavy metals — not cannabinoid potency alone
- Start with the lowest available dose and wait for full onset before considering additional use
- With edibles, allow at least 90 minutes before any additional consumption
- Avoid driving or operating machinery — no impairment studies exist, and standard drug screens detect THC isomers[15]
- Keep all products stored securely away from children — pediatric accidental ingestion is the most common exposure route in poison center data[5]
- If using vape products, avoid cartridges with added cutting agents or unknown ingredients
Aftercare & Integration
Δ10-THC experiences are generally mild and rarely require formal integration. If lingering anxiety, mood disruption, or sleep problems follow use, basic recovery applies: hydrate, eat a balanced meal, and rest in a calm environment.
For anyone who had an unexpectedly intense or distressing experience — particularly from edibles where dosing is imprecise — talking through it with a trusted person can help resolve residual unease. Persistent anxiety or mood changes lasting more than a few days warrant speaking with a healthcare provider.
Recovery & Support
No dependence data exist specifically for Δ10-THC. Anyone finding cannabinoid use has become compulsive or difficult to stop can access resources designed for cannabis use concerns. SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals. Marijuana Anonymous and SMART Recovery provide peer support.
Cannabis withdrawal, when it occurs, typically resolves within 2–6 days and involves irritability, sleep disruption, appetite changes, and craving.[14] Professional support can help manage these symptoms.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most Δ10-THC adverse events involve manageable discomfort — elevated heart rate, anxiety, or sedation. Seek immediate medical help if any of the following occur:
- Chest pain or severe heart pounding
- Loss of consciousness or inability to be roused
- Seizures
- Severe breathing difficulty
- Extreme agitation with risk of self-harm
Immediate steps:
- Call emergency services if any of the above signs are present
- Move the person to a quiet, safe space
- If unconscious but breathing, place in the recovery position (on their side)
- Do not induce vomiting if the substance was ingested
- Monitor breathing and heart rate until help arrives
What to tell the dispatcher: Name the substance (Δ10-THC or "a hemp-derived THC product"), estimated amount consumed, time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
Δ10-THC's legal status depends on whether a jurisdiction controls all THC isomers generically or only specific variants — and in the United States, on whether converting CBD to Δ10-THC counts as chemical synthesis.[16]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Contested — Schedule I if synthetically derived; potentially legal if hemp-derived | The 2018 Farm Bill legalized hemp-derived cannabinoids with less than 0.3% Δ9-THC by dry weight. The DEA's April 2026 rescheduling order explicitly excludes tetrahydrocannabinols "derived only through artificial synthesis" from Schedule III reclassification, citing Δ10-THC as an example.[17] Whether CBD-to-Δ10-THC conversion constitutes "synthesis" is actively contested.[7] |
| United States (state) | Variable — approximately 30+ states permit; 15+ states ban | States including Alaska, Arizona, Colorado, Hawaii, Idaho, Iowa, Montana, Nevada, and Utah have explicitly banned Δ10-THC or all chemically converted cannabinoids. State laws change frequently. Online retailers frequently ship regardless of local restrictions.[18] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | All THC stereoisomers and structural isomers are controlled. Δ10-THC is unambiguously controlled. |
| European Union | Controlled (generic THC scheduling) | THC and its isomers are controlled across EU member states. Δ10-THC falls under generic cannabinoid control in virtually all jurisdictions. |
| Canada | Controlled (Cannabis Act / CDSA Schedule II) | All tetrahydrocannabinols are controlled generically. No legal pathway for commercial Δ10-THC products outside the regulated cannabis framework. |
| Australia | Controlled (Poisons Standard, Schedule 8) | Cannabinoid analogs are controlled under generic scheduling. Not available for commercial sale without TGA authorization. |
Analog and conversion considerations
The central US legal question is whether acid-catalyzed conversion of CBD to Δ10-THC constitutes synthetic production. The hemp industry argues it does not; federal regulators have signaled the opposite. This has not been definitively resolved by federal courts as of May 2026, and the regulatory trend across US states is toward restricting chemically converted cannabinoids.[7][16]
Legal status changes frequently and varies by jurisdiction. This information reflects conditions as of May 2026 and is not legal advice.
references
- [1]
- [2] ^abSrebnik M, Lander N, Breuer A, Mechoulam R (1984) Base-catalysed double-bond isomerizations of cannabinoids: structural and stereochemical aspects — Journal of the Chemical Society, Perkin Transactions 1 doi:10.1039/p19840002881
- [3]
- [4]
- [5]
- [6] ^abcdRay CL, Bylo MP, Pescaglia J, Gawenis JA, Greenlief CM (2022) Delta-8 Tetrahydrocannabinol Product Impurities — Molecules doi:10.3390/molecules27206924